TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.
Follow-Up Questions
¿Quién es el CEO de TC Biopharm (Holdings) PLC?
Mr. Bryan Kobel es el Chief Executive Officer de TC Biopharm (Holdings) PLC, se unió a la empresa desde 2021.
¿Qué tal es el rendimiento del precio de la acción TCBPY?
El precio actual de TCBPY es de $0.18, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de TC Biopharm (Holdings) PLC?
TC Biopharm (Holdings) PLC pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de TC Biopharm (Holdings) PLC?
La capitalización bursátil actual de TC Biopharm (Holdings) PLC es $1.8M
¿Es TC Biopharm (Holdings) PLC una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para TC Biopharm (Holdings) PLC, incluyendo 3 fuerte compra, 5 compra, 1 mantener, 0 venta, y 3 fuerte venta
